Skip to main content
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Claudia Pauligk
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy – final results of the phase II RE-ExPEL study
BackgroundBased on results of prior trials (TAGS, REGARD, RAINBOW), it seems promising to combine Ramucirumab (Ram) beyond progression (PD) with TAS-102 (trifluridine/tipiracil). The purp...
Alexander Stein ;
Timorshah Habibzada ;
Peter Herhaus ;
E. Goekkurt ;
Disorn Sookthai ;
Tanita Brulin ;
Kristina Ihrig ;
Claudia Pauligk ;
Salah-Eddin Al-Batran , MD;
Sylvie Lorenzen ;
Thorsten Goetze ;
06/25/2023
Featured CME Course
Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes
Upcoming Events
February 2 – February 5
February 7 – February 9
February 27 – March 1
March 17 – March 19
March 22 – March 23
March 27 – March 30
March 31 – April 2
April 21 – April 24
April 30 – May 4
May 1 – May 3
See Full Calendar